mTORC1 and BMP-Smad1/5 regulation of serum-stimulated myotube hypertrophy: a role for autophagy.

Autor: Zhang Q; Integrative Muscle Biology Laboratory, Division of Rehabilitation Sciences, College of Health ProfessionsUniversity of Tennessee Health Science Center, Memphis, Tennessee, United States., Halle JL; Integrative Muscle Biology Laboratory, Division of Rehabilitation Sciences, College of Health ProfessionsUniversity of Tennessee Health Science Center, Memphis, Tennessee, United States., Counts BR; Integrative Muscle Biology Laboratory, Division of Rehabilitation Sciences, College of Health ProfessionsUniversity of Tennessee Health Science Center, Memphis, Tennessee, United States., Pi M; Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, United States., Carson JA; Huffines Institute for Sports Medicine & Human Performance, Department of Kinesiology & Sports Management , Texas A&M University, College Station, Texas, United States.
Jazyk: angličtina
Zdroj: American journal of physiology. Cell physiology [Am J Physiol Cell Physiol] 2024 Jul 01; Vol. 327 (1), pp. C124-C139. Date of Electronic Publication: 2024 May 20.
DOI: 10.1152/ajpcell.00237.2024
Abstrakt: Protein synthesis regulation is critical for skeletal muscle hypertrophy, yet other established cellular processes are necessary for growth-related cellular remodeling. Autophagy has a well-acknowledged role in muscle quality control, but evidence for its role in myofiber hypertrophy remains equivocal. Both mammalian target of rapamycin complex I (mTORC1) and bone morphogenetic protein (BMP)-Smad1/5 (Sma and Mad proteins from Caenorhabditis elegans and Drosophila , respectively) signaling are reported regulators of myofiber hypertrophy; however, gaps remain in our understanding of how this regulation is integrated with growth processes and autophagy regulation. Therefore, we investigated the mTORC1 and Smad1/5 regulation of protein synthesis and autophagy flux during serum-stimulated myotube growth. Chronic serum stimulation experiments were performed on day 5 differentiated C2C12 myotubes incubated in differentiation medium [2% horse serum (HS)] or growth medium [5% fetal bovine serum (FBS)] for 48 h. Rapamycin or LDN193189 was dosed for 48 h to inhibit mTORC1 and BMP-Smad1/5 signaling, respectively. Acute serum stimulation was examined in day 7 differentiated myotubes. Protein synthesis was measured by puromycin incorporation. Bafilomycin A1 and immunoblotting for LC3B were used to assess autophagy flux. Chronic serum stimulation increased myotube diameter 22%, total protein 21%, total RNA 100%, and Smad1/5 phosphorylation 404% and suppressed autophagy flux. Rapamycin, but not LDN193189, blocked serum-induced myotube hypertrophy and the increase in total RNA. Acute serum stimulation increased protein synthesis 111%, Smad1/5 phosphorylation 559%, and rpS6 phosphorylation 117% and suppressed autophagy flux. Rapamycin increased autophagy flux during acute serum stimulation. These results provide evidence for mTORC1, but not BMP-Smad1/5, signaling being required for serum-induced myotube hypertrophy and autophagy flux by measuring LC3BII/I expression. Further investigation is warranted to examine the role of autophagy flux in myotube hypertrophy. NEW & NOTEWORTHY The present study demonstrates that myotube hypertrophy caused by chronic serum stimulation requires mammalian target of rapamycin complex 1 (mTORC1) signaling but not bone morphogenetic protein (BMP)-Smad1/5 signaling. The suppression of autophagy flux was associated with serum-induced myotube hypertrophy and mTORC1 regulation of autophagy flux by measuring LC3BII/I expression. Rapamycin is widely investigated for beneficial effects in aging skeletal muscle and sarcopenia; our results provide evidence that rapamycin can regulate autophagy-related signaling during myotube growth, which could benefit skeletal muscle functional and metabolic health.
Databáze: MEDLINE